The global cardiac biomarker market is expected to generate the revenue of $2,225.9 million by 2022, registering a CAGR of 19.5% from 2016 to 2022. The prevention of cardiac diseases, by active monitoring the heart conditions by using cardiac biomarker testing is the newest approach for obtaining fastest output of immediate diagnosing and treatment of cardiac deceases. Cardiac biomarkers are made by protein-based traceable substances used as an indicator to assess biological state and for diagnosing the proactive purposes associated with heart. Cardiac biomarkers are also used as risk calculation for various cardiovascular diseases (CVDs), including myocardial congestive heart failure, infraction, acute coronary syndrome (ACS) among others deceases.
For more information about this report: http://www.reportsweb.com/global-cardiac-biomarkers-market-insights-opportunity-analysis-market-shares-and-forecast-2016-2022
The promising features of markers such as high accuracy, rapid outcomes and affordable pricing of cardiac point of care (POC) testing is supporting the market of cardiac biomarker for the growth, worldwide. To keep the momentum stable of cardiac marker tests, the key manufacturers offers customized solutions. However, limited availability in some cases and side effects such as skeletal muscle injury is hindering the growth of cardiac biomarkers market. However, concerns related to single measurement cardiac biomarkers, high pricing of the devices and certain government regulations is expected to restrain the market to grow.
The global cardiac biomarkers market is basically segmented on the basis of type, application, location of testing and geography. Based on type of cardiac biomarkers, the market is divided into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the largest revenue-generating segment in the overall cardiac biomarkers market because of its prodigious specialty and its ability to detect accurately the cardiac events of Acute Coronary Syndrome (ACS).
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001329469/sample
Based on application segment, the market is subdivided into myocardial infarction, congestive heart failure, atherosclerosis acute coronary syndrome, and others. Myocardial infarction (MI) accounts the highest market share in the global cardiac biomarker market and it is followed by acute coronary syndrome (ACS) because of its highest prevalence rate in all the cardiovascular diseases (CVDs). The location of testing segment is classified under point of care testing and laboratory testing. Doctors and clinicians majorly use point of care cardiac testing for quick monitoring and diagnosing patients with having chest pain in an emergency care unit, therefore, it accounts for the fastest growing CAGR in the forecasted period. However, laboratory testing segment is generating larger revenue in comparison to point of care testing now-a-days.
On the basis of geography, the global cardiac biomarker market is divided into North America, Europe, Asia-Pacific and LAMEA. Out of which North America is leading the global market, owing to the high demand for cardiac testing, high CVD prevalence rates and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is emerging region with fastest growing CAGR due to the modernization in the countries, increasing disposable incomes and increasing affordability for the advanced cardiac treatments.
Key companies working in this market are Roche Diagnostics, Siemens Healthcare, Becton, Alere Inc., BioMerieux, Abbott Laboratories, Bio-Rad Laboratories, Dickinson and Company, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global market. Biomarkers production companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.
1. ABBOTT DIAGNOSTICS
2. ALERE INC.
3. BECKMAN COULTER
4. BECTON, DICKINSON AND CO.
5. BG MEDICINE INC.
7. EKF DIAGNOSTICS HOLDINGS, INC.
8. MERCK & CO, INC.
9. RADIOMETER MEDICAL
10. RANDOX LABORATORY
11. RESPONSE BIOMEDICAL
12. ROCHE HOLDING AG
13. SIEMENS HEALTHCARE
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001329469/buying